Extracorporeal photopheresis: a useful therapy for patients with steroid‐refractory acute graft‐versus‐host disease but not for the prevention of the chronic form. (13th August 2013)

• Record Type: Journal Article
• Authors: Rubegni, P.; Feci, L.; Poggiali, S.; Marotta, G.; D'Ascenzo, G.; Murdaca, F.; Fimiani, M.
• Is Part Of: British journal of dermatology. Volume 169:Number 2(2013:Aug.)
• Page Start: 450
• Page End: 457
• Publication Date: 2013-08-13
• Subjects: Dermatology -- Periodicals; Skin -- Diseases -- Periodicals; 616.5
• DOI: 10.1111/bjd.12332
• Languages: English
• ISSNs: 0007-0963

Abstract

<abstract abstract-type="short" xml:lang="en" id="bjd12331-abs-0002"> <title> <x xml:space="preserve">Abstract</x> </title> <p> <bold>What's already known about this topic?</bold> </p> <p> <list id="bjd12332-list-0001" list-type="bullet"> <list-item> <p>Extracorporeal photopheresis (ECP) has been used successfully to treat severe steroid‐refractory acute and chronic graft‐versus‐host disease (aGVHD, cGVHD) since the late 1990s.</p> </list-item> </list> </p> <p> <bold>What does this study add?</bold> </p> <p> <list id="bjd12332-list-0002" list-type="bullet"> <list-item> <p>ECP is effective in patients with mild to moderate steroid‐refractory aGVHD (grade II–III). On the other hand, ECP did not prevent the development of cGVHD in our patients.</p> </list-item> </list> </p> </abstract>